文献速递膀胱癌与上尿路尿路上皮癌

临床淋巴结阳性膀胱癌诱导化疗的最佳周期数

The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer.
PubMed 文献 · BJU Int · 2024-03-12

该研究纳入388例接受3或4周期顺铂/吉西他滨或(剂量密集)MVAC方案诱导化疗后行巩固性根治性膀胱切除术的cTanyN1-3M0膀胱癌患者,比较病理完全缓解(pCR)、客观缓解(pOR)及生存结局;结果显示3周期与4周期组的pCR、pOR及总生存、癌症特异性生存均无显著差异。

要点

  • 388例cN+膀胱癌患者中,101例接受3周期、287例接受4周期诱导化疗。
  • 3周期与4周期组的pCR率(20% vs 18%)和pOR率(40% vs 31%)均无显著差异。
  • 3周期与4周期组2年总生存估计分别为63%(95%CI 0.53-0.74)和63%(95%CI 0.58-0.7)。

核心结论

  • 在cN+膀胱癌患者中,给予3或4周期诱导化疗的病理缓解和生存结局无差异。
  • 作者认为较少周期(至少3周期)在肿瘤学上可能足够,同时可缩短对化疗无缓解患者等待确定性局部治疗的时间;该结论需进一步验证。

研究设计与样本

  • 研究纳入388例接受3或4周期顺铂/吉西他滨或(剂量密集)MVAC方案诱导化疗后行巩固性根治性膀胱切除术加盆腔淋巴结清扫的cTanyN1-3M0膀胱癌患者。
  • 比较治疗组间的病理完全缓解(pCR=ypT0N0)和客观缓解(pOR=yp≤T1N0),采用单变量和多变量逻辑回归分析评估pCR和/或pOR的预测因素。
  • 次要终点为总生存(OS)和癌症特异性生存(CSS),采用多变量Cox回归评估诱导化疗周期数与生存结局的关联。

主要发现

  • 101例和287例患者分别接受3周期和4周期诱导化疗。
  • 72例(19%)和128例(33%)分别达到pCR和pOR。
  • 3周期与4周期组的pCR率(20% vs 18%)和pOR率(40% vs 31%)无显著差异(P>0.05)。
  • 多变量逻辑回归分析显示周期数与pCR或pOR无关联。
  • 3周期与4周期组2年OS估计分别为63%(95%CI 0.53-0.74)和63%(95%CI 0.58-0.7);单变量和多变量Cox回归分析显示接受3周期 vs 4周期与OS和CSS无关联。

局限性

  • 作者指出该结论需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the optimal number of induction chemotherapy cycles needed to achieve a pathological response in patients with clinically lymph node-positive (cN+) bladder cancer (BCa) who received three or four cycles of induction chemotherapy followed by consolidative radical cystectomy (RC) with pelvic lymph node dissection. PATIENTS AND METHODS: We included 388 patients who received three or four cycles of cisplatin/gemcitabine or (dose-dense) methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), followed by consolidative RC for cTanyN1-3M0 BCa. We compared pathological complete (pCR = ypT0N0) and objective response (pOR = yp ≤T1N0) between treatment groups. Predictors of pCR and/or pOR were assessed using uni- and multivariable logistic regression analysis. The secondary endpoints were overall (OS) and cancer-specific survival (CSS). We evaluated the association between the number of induction chemotherapy cycles administered and survival outcomes on multivariable Cox regression. RESULTS: Overall, 101 and 287 patients received three or four cycles of induction chemotherapy, respectively. Of these, 72 (19%) and 128 (33%) achieved pCR and pOR response, respectively. The pCR (20%, 18%) and pOR (40%, 31%) rates did not differ significantly between patients receiving three or four cycles (P > 0.05). The number of cycles was not associated with pCR or pOR on multivariable logistic regression analyses. The 2-year OS estimates were 63% (95% confidence interval [CI] 0.53-0.74) and 63% (95% CI 0.58-0.7) for patients receiving three or four cycles, respectively. Receiving three vs four cycles was not associated with OS and CSS on uni- or multivariable Cox regression analyses. CONCLUSION: Pathological response and survival outcomes did not differ between administering three or four induction chemotherapy cycles in patients with cN+ BCa. A fewer cycles (minimum three) may be oncologically sufficient in patients with cN+ BCa, while decreasing the wait for definitive local therapy in those patients who end up without a response to chemotherapy. This warrants further validation.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. von Deimling M, Mertens LS, Furrer M, et al. The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer. BJU Int. 2024. PMID: 38470089. doi:10.1111/bju.16319

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。